ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016
Codominant Role of Interferon-γ- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection.The Journal of clinical investigation · 2021Trial
- Chronic Rejection in Facial Vascularized Composite Allotransplantation (fVCA).Results and problems in cell differentiation · 2026Review
- Molecular Signature Associated With Acute Rejection in Vascularized Composite Allotransplantation.Transplantation direct · 2024Article
- Immunogenicity and tolerance induction in vascularized composite allotransplantation.Frontiers in transplantation · 2024Review
- Cellular activation pathways and interaction networks in vascularized composite allotransplantation.Frontiers in immunology · 2023Review
- Peripheral nerve repair is associated with augmented cross-tissue inflammation following vascularized composite allotransplantation.Frontiers in immunology · 2023Article
- T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation.Cell reports. Medicine · 2022Article
- Non-HLA Antibodies in Hand Transplant Recipients Are Connected to Multiple Acute Rejection Episodes and Endothelial Activation.Journal of clinical medicine · 2022Article
- FK506-loaded PLGA nanoparticles improve long-term survival of a vascularized composite allograft in a murine model.Annals of translational medicine · 2021Article
- The Effects of Tacrolimus on Tissue-Specific, Protein-Level Inflammatory Networks in Vascularized Composite Allotransplantation.Frontiers in immunology · 2021Article
- Article
- Abnormal Nailfold Capillaries in Patients after Hand Transplantation.Journal of clinical medicine · 2020Article
- IL-27 RαJournal of cellular and molecular medicine · 2020Article
- Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation.Scientific data · 2019Article
- The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation.JAMA facial plastic surgery · 2019Article
- MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study.Frontiers in immunology · 2019Article
- Increased levels of circulating MMP3 correlate with severe rejection in face transplantation.Scientific reports · 2018Article
- Kidney Dysfunction After Vascularized Composite Allotransplantation.Transplantation direct · 2018Article
- Longitudinal immunological characterization of the first presensitized recipient of a face transplant.JCI insight · 2017Article
- Immunological Characteristics of a Patient With Belatacept-Resistant Acute Rejection After Face Transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Facial transplantation is a life-changing procedure for patients with severe composite facial defects. However, skin is the most immunogenic of all transplants, and better understanding of the immunological processes after facial transplantation is of paramount importance. Here, we describe six patients who underwent full facial transplantation at our institution, with a mean follow-up of 2.7 years. Seum, peripheral blood mononuclear cells, and skin biopsy specimens were collected prospectively, and a detailed characterization of their immune response (51 time points) was performed, defining 47 immune cell subsets, 24 serum cytokines, anti-HLA antibodies, and donor alloreactivity on each sample, producing 4269 data points. In a nonrejecting state, patients had a predominant T helper 2 cell phenotype in the blood. All patients developed at least one episode of acute cellular rejection, which was characterized by increases in interferon-γ/interleukin-17-producing cells in peripheral blood and in the allograft's skin. Serum monocyte chemotactic protein-1 level was significantly increased during rejection compared with prerejection time points. None of the patients developed de novo donor-specific antibodies, despite a fourfold expansion in T follicular helper cells at 1 year posttransplantation. In sum, facial transplantation is frequently complicated by a codominant interferon-γ/interleukin-17-mediated acute cellular rejection process. Despite that, medium-term outcomes are promising with no evidence of de novo donor-specific antibody development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.